TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

THIOLA

TIOPRONIN Cystine Disulfide Reduction
Approved 1988-08-11
1
Indication
--
Phase 3 Trials
1
Priority Reviews
37
Years on Market

Details

Status
Prescription
First Approved
1988-08-11
Routes
ORAL
Dosage Forms
TABLET

Companies

Active Ingredient: TIOPRONIN

THIOLA Approval History

Loading approval history...

What THIOLA Treats

1 indications

THIOLA is approved for 1 conditions since its original approval in 1988. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Cystinuria
Source: FDA Label
๐Ÿ”ฌ

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
โญ

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
๐Ÿ“Š

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

THIOLA FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

THIOLA is indicated, in combination with high fluid intake, alkali, and diet modification, for the prevention of cystine stone formation in adults and pediatric patients 20 kg and greater with severe homozygous cystinuria, who are not responsive to these measures alone. --------------------------------------------INDICATIONS AND USAGE----------------------------------------- THIOLA is a reducing and complexing thiol indicated, in combination with high fluid intake, alkali, and diet modification, for the prevention of cystine stone formation in adults and pediatric patients 20 kg and greater wi...

THIOLA Patents & Exclusivity

Exclusivity: Jun 2026

Exclusivity

ODE-267 Until Jun 2026
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.